- Exclusive agreement expands access to AGAMREE® across selected markets in Latin American and the Caribbean, including Brazil, Colombia and Argentina.
- Through this partnership, SteinCares reinforces its position as a strategic bridge between global pharmaceutical innovation and Latin America’s healthcare needs, strengthening its rare disease portfolio while expanding Santhera’s international distribution network.
San Jose, Costa Rica, November 2026 – Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on rare diseases, and SteinCares, a leading specialty healthcare company in Latin America, have announced an exclusive distribution agreement to bring AGAMREE® (vamorolone), an innovative treatment for Duchenne muscular dystrophy (DMD) to selected markets in Latin America and the Caribbean.
The partnership brings AGAMREE® to a region where approximately 15,000 people are living with DMD.¹ The launch will initially focus on Brazil, where SteinCares will advance the ANVISA registration process while supporting access through the applicable local pathways. The rollout will then expand to additional selected markets throughout the region, subject to applicable regulatory approvals.
The agreement brings together Santhera’s expertise in rare neuromuscular diseases with SteinCares’ in-depth specialty care knowledge and its integrated one-stop-shop platform, which encompasses regulatory affairs, market access, supply chain management, commercialization and distribution, among other capabilities.
“We are delighted to partner with Santhera to bring AGAMREE® to patients with DMD in Latin America,” said Sebastian Katz, Chief Strategy Officer at SteinCares. “This agreement strengthens our rare disease portfolio and reflects our role as a strategic bridge between global pharmaceutical innovation and the healthcare needs of Latin America. By combining Santhera’s expertise in rare neuromuscular diseases with SteinCares’ regional platform and deep understanding of local healthcare systems, we aim to help expand sustainable access to innovative treatment options for patients across the region.”
“This agreement is an important step towards bringing AGAMREE® to patients with DMD in Latin America and the Caribbean,” said Orlando Oliveira, Chief Executive Officer of Santhera. “It expands our international distribution network, building on our partnerships across North America, Central and Eastern Europe, Asia and the Middle East. SteinCares’ established expertise in market access and proven commercial launch capabilities across the region will be key as we work toward initial patient access in Brazil and a phased rollout across further markets.”
1 Based on global DMD prevalence estimates
About SteinCares
SteinCares is a leading specialty pharmaceutical company dedicated to expanding patient access to innovative and cost-effective treatments across Latin America. With more than 45 years of experience and an integrated “one-stop-shop” platform across 30 countries of Latin America and the Caribbean, SteinCares combines deep local expertise, regulatory agility, and end-to-end operational capabilities — from licensing and commercialization to market access and patient support.
For more information, please visit http://www.steincares.com/ or follow the company on LinkedIn.
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative corticosteroid with a novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE® for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Commission (EC), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in Switzerland by Swissmedic, in China by the National Medical Products Administration (NMPA), in Hong Kong by the Department of Health (DoH) and in Canada by Health Canada. Santhera has out-licensed the rights to AGAMREE® as follows: to Catalyst Pharmaceuticals for North America; to Sperogenix Therapeutics for China and certain countries in Southeast Asia; and to Nxera Pharma for Japan, South Korea, Australia, and New Zealand. For further information, please visit www.santhera.com.
AGAMREE® is a trademark of Santhera Pharmaceuticals.
